Global Deals Top $2.6 Trillion in First Half of Year

Global deal values rose about 30% YoY to $2.6 trillion in the first half, signaling an ongoing deal cycle. Commentary from Bloomberg frames this as a “Trump-induced M&A boom,” suggesting improved risk appetite and supportive capital deployment. Overall, the update is positive for transaction-volume expectations, though it is not a specific company or policy figure.

Analysis

The first-order winner is the advisory stack, but the cleaner expression is the independent advisers rather than the universal banks. Deal fees are high-margin and highly levered to volumes, so even a modest continuation in announced transactions can drive outsized estimate upside for EVR, PJT, and MOE, with GS/MS benefiting secondarily through financing, bridge lending, and ECM follow-on flow. The less obvious beneficiary is event-driven and merger-arb capital: a richer target pipeline plus a friendlier antitrust backdrop typically lowers idiosyncratic discount rates and improves spread capture.

The losers are the acquirers that need equity currency or expensive debt to fund growth, especially in software, industrials, and healthcare services where multiple expansion has already been pulled forward. More M&A also raises the probability of “bad” consolidation: short-term EPS accretion can mask longer-dated integration drag, meaning the market may initially reward announcers but punish them after the close if synergies disappoint or leverage stays elevated. Competitors of acquired firms can also lose pricing power as larger combined entities force procurement concessions and distribution dominance.

This is mostly a 1-3 month flow trade, not a clean 12-month fundamental rerating. The key reversal trigger is credit: if high-yield spreads widen, loan markets cheapen, or rates back up, sponsor and strategic leverage math breaks quickly. The contrarian view is that a M&A surge is often late-cycle behavior; consensus may be overestimating policy-driven deal durability while underestimating how quickly antitrust, financing, or macro volatility can shut the window.

Key Decisions for Investors

• Long EVR / PJT vs XLF for 1-3 months: best pure exposure to fee leverage; exit if announced deal volume rolls over or advisory pipelines weaken on earnings.
• Buy 3-month call spreads on GS or MS into the next earnings season: asymmetric upside if ECM, financing, and advisory revenues inflect; cut if investment-banking backlog disappoints.
• Add KKR or BX on a 6-12 month horizon if exits and sponsor deal flow improve; the catalyst is realizations, but thesis fails if credit spreads widen materially.
• Keep a short watchlist on highly levered serial acquirers in software/healthcare/industrials; short only after a deal announcement if the stock gaps up on synergy claims and leverage is >3.5x.
• Alert level: if HY spreads widen >75-100 bps from here or LBO financing windows tighten, fade the M&A beta trade and reduce adviser longs.